Tumor Biology Program

项目概要-肿瘤生物学项目 肿瘤生物学项目是艾布拉姆森癌症中心的两个基础科学研究项目之一 （行政协调会）。该计划旨在促进ACC内的研究，以促进对机制的理解 潜在的肿瘤发生，并确定途径，这将使新的预防，诊断，预后和 癌症的治疗方法。自20世纪70年代初成立以来，肿瘤生物学计划已 继续响应癌症研究的新兴领域和进展。目前，该计划正在组织 围绕三个中心目标：1）阐明癌症的分子和细胞基础; 2）了解 癌症的表观遗传学;和3）研究肿瘤微环境和转移进展。成员 肿瘤生物学是高度互动的，跨相关的科学主题进行程序内合作， 每个目标包括基因组完整性，细胞信号传导，代谢和病毒途径，着眼于癌症， 最高的负担或健康差距在我们的集水区。肿瘤生物学的突破性发现 发现了上皮-间质转化的新机制，癌症药物的转录控制 敏感性，炎症的表观遗传调节，前列腺癌中雄激素抵抗的新机制， 以及病毒模仿的免疫逃避。新的目标是翻译到诊所与其他合作 早期发现和治疗方案。肿瘤生物学项目由新的充满活力的项目领导 共同领导人（PL）Shelley Berger博士和Sandra Ryeom博士，他们共同促进了有影响力的内部和 通过各种创新方法开展方案间合作。PL在招聘中发挥着重要作用 新成员，指导初级教师，促进教师之间的互动和会议，以及 组织会议和专题讨论会。肿瘤生物学项目成员在培训中发挥关键作用， 高中生，博士生，医学博士/博士生，以及医学博士或博士博士后研究员的导师 癌症相关的研究，通过他们在宾夕法尼亚大学生物医学研究生的领导作用 研究（BGS），MD/PhD计划（MSTP）和NIH T32培训赠款。肿瘤的持续成功 生物学计划是由其成员的特殊科学进步证明，通过 与多机构、方案间和方案内合作的高影响力出版物， 对癌症生物学的深入了解。目前，该计划有来自20个部门和5个部门的53名成员。 不同的学校，总资金为2570万美元（每年的直接费用），其中2000万美元是同行评审的，640万美元是 是国家癌症研究所资助的该计划有67个R 01当量。自2015年以来，肿瘤生物学项目成员发表了 617篇癌症相关论文，其中15%是程序内的，29%是程序间的，62%是程序间的。 是多机构的。

PROJECT SUMMARY – Tumor Biology Program The Tumor Biology Program is one of two basic science Research Programs of the Abramson Cancer Center (ACC). This Program aims to catalyze research within the ACC to advance an understanding of mechanisms underlying tumorigenesis and to identify pathways that will enable novel preventive, diagnostic, prognostic and therapeutic approaches to cancer. Since its inception in the early 1970s, the Tumor Biology Program has continued to respond to emerging areas and advances in cancer research. The Program is currently organized around three central Aims: 1) Elucidate the molecular and cellular basis underlying cancer; 2) Understand the epigenetics of cancer; and 3) Investigate the tumor microenvironment and metastatic progression. Members of Tumor Biology are highly interactive, collaborating intra-Programmatically across scientific topics relevant to each Aim including genome integrity, cell signaling, metabolism, and viral pathways, with an eye on cancers of highest burden or health disparity in our catchment area. Ground-breaking discoveries in Tumor Biology uncovered novel mechanisms of epithelial-mesenchymal transition, transcriptional control of cancer drug sensitivity, epigenetic regulation of inflammation, novel mechanisms of androgen-resistance in prostate cancer, and immune evasion by viral mimicry. New targets were translated to the clinic in collaboration with other Programs for early detection and treatment. The Tumor Biology Program is led by new and energetic Program co-Leaders (PLs) Shelley Berger, PhD and Sandra Ryeom, PhD, who together catalyze impactful intra- and inter-Programmatic collaborations by a variety of innovative methods. The PLs are instrumental in recruiting new members, mentoring junior faculty, stimulating interactions and meetings among faculty members, and organizing conferences and symposia. Tumor Biology Program members play key roles in the training and mentorship of high school students, PhD students, MD/PhD students, and MD or PhD postdoctoral fellows in cancer-related research through their leadership roles in the University of Pennsylvania Biomedical Graduate Studies (BGS), MD/PhD program (MSTP) and NIH T32 training grants. The continued success of the Tumor Biology Program is evidenced by the exceptional scientific progress of its members, demonstrated through high-impact publications with multi-institutional, inter- and intra-Programmatic collaborations, offering key insights into the biology of cancer. Currently, the Program has 53 members from 20 departments and five different schools with total funding of $25.7M (annual direct costs) of which 20.0M is peer-reviewed and $6.4M is NCI-funded. The Program has 67 R01-equivalents. Since 2015, Tumor Biology Program members published 617 cancer-related papers, of which 15% were intra-Programmatic, 29% were inter-Programmatic, and 62% were multi-institutional.